Cargando…

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

PURPOSE OF REVIEW: Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic treatment for advanced melanoma. Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albrecht, Lea Jessica, Livingstone, Elisabeth, Zimmer, Lisa, Schadendorf, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164023/ https://www.ncbi.nlm.nih.gov/pubmed/37004702 http://dx.doi.org/10.1007/s11912-023-01406-4

Ejemplares similares

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
por: Ascierto, Paolo Antonio, et al.
Publicado: (2023)

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
por: Thudium, Kent, et al.
Publicado: (2022)

Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanoma—a case report
por: Cerbon, Danielle, et al.
Publicado: (2023)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

TIPS-04 A RANDOMIZED, MULTI-INSTITUTIONAL PILOT STUDY TO EVALUATE THE MOLECULAR AND CELLULAR RESPONSE TO TREATMENT WITH NIVOLUMAB WITH EITHER ADJUVANT IPILIMUMAB OR RELATLIMAB IN ADULT PATIENTS WITH SURGICALLY RESECTABLE MELANOMA BRAIN METASTASES: ONGOING TRIAL
por: Pina, Yolanda, et al.
Publicado: (2023)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry
por: Pohl, Julia, et al.
Publicado: (2020)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis
por: Sondermann, Wiebke, et al.
Publicado: (2016)

Melanoma Management: From Epidemiology to Treatment and Latest Advances
por: Lopes, Joana, et al.
Publicado: (2022)

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
por: Chokr, Nora, et al.
Publicado: (2018)

Latest Treatment Option and Technology Advancement in Corneal and Ocular Surface Disease
por: Costagliola, Ciro, et al.
Publicado: (2014)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition
por: Hegedüs, Luca, et al.
Publicado: (2022)

Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
por: Fujimura, Taku, et al.
Publicado: (2017)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
por: Hegedüs, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m0vcd4mo8n89vcosbqs29rrp4o